|
Arthritis, Psoriatic
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.
|
30552173 |
2019 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Amino acids measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide association study identifies novel genetic variants contributing to variation in blood metabolite levels.
|
26068415 |
2015 |
|
Amino acids measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
|
27005778 |
2016 |
|
Protein measurement
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA.
|
27005778 |
2016 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Serum albumin measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genome-wide association study identifies multiple loci influencing human serum metabolite levels.
|
22286219 |
2012 |
|
Mean Corpuscular Volume (result)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Seizures
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Overall, the neurotoxic profile of Tat1-86 appeared more profound in the developing nervous system in vivo relative to that seen with the first exon encoded Tat1-72 (Fitting et al., 2008b), as noted on measures of eye opening, righting reflex, and PPI.
|
25285887 |
2014 |
|
Carcinoma of urinary bladder, invasive
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
|
31443960 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Activity of human immunodeficiency virus type 1 promoter/TAR regions and tat1 genes derived from individuals with different rates of disease progression.
|
9191845 |
1997 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The RNA expression of PAX5 was evaluated with reverse transcriptase polymerase chain reaction in the tumor tissue of 75 patients with stage TaT1 bladder cancer treated with transurethral resection.
|
16566978 |
2006 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
DNA cytometric features in biopsies of TaT1 urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality.
|
12809927 |
2003 |
|
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.
|
12783972 |
2003 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirty-nine patients with depression were randomly assigned to immediate MCT (10 sessions) or a 10-week wait list period (WL).
|
28174547 |
2017 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thirty-nine patients with depression were randomly assigned to immediate MCT (10 sessions) or a 10-week wait list period (WL).
|
28174547 |
2017 |
|
Drug habituation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Tat1-86 induced developmental neurotoxic effects, as witnessed by delays in eye opening, delays in early reflex development and alterations in prepulse inhibition (PPI) and between-session habituation of locomotor activity.
|
25285887 |
2014 |
|
Euthyroid Sick Syndromes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, we aimed to evaluate the central and peripheral expression of genes involved in the transport (MCT8/<i>Slc16a2</i> and MCT10/<i>Slc16a10</i>), metabolism (<i>Dio1, Dio2</i>, and <i>Dio3</i>) and action (<i>Thra</i> and <i>Thrb</i>) of TH during NTIS induced by fasting or sepsis.
|
29118715 |
2017 |
|
Hypothyroidism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Low T4 was observed in preterm infants irrespective of the cause of preterm birth, while maternal (TSH) and placental (DiO2, DiO3, and MCT10) compensatory responses were only activated in indicated preterm birth due to vascular complications.
|
29557697 |
2019 |
|
Low T3 Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We examined the role of TH transporters monocarboxylate transporter 8 (MCT8, also known as SLC16A2) and MCT10 in the pathogenesis of the low T(3) syndrome in prolonged critical illness.
|
19439506 |
2009 |
|
Lymphoma, Follicular
|
0.010 |
Biomarker
|
disease |
BEFREE |
A spontaneously EBV transformed follicular lymphoma (FL) cell line, Tat-1, was established from the lymph node biopsy specimen of a patient with B cell FL, grade 1 in transformation to high grade disease.
|
11840295 |
2002 |
|
nervous system disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Together, these results demonstrate that the neurotoxic epitope of Tat(1-72) is different from the epitope that is indirectly neurotoxic following production of TNF-alpha from immune cells, and suggest that therapeutic interventions against TNF-alpha might be beneficial against HIV-1 associated neurological disorders.
|
17451964 |
2007 |